Prenetics Global logo

Prenetics Global(NASDAQ) PRE

Market Cap$376.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-80%
5 Year-85%
1 Year+50%
1 Month-15%
Premium Feature
Moneyball Superscore
65/100
$21.95
-5.10%
-1.18Today
Prenetics Global last closing stock price
MetricPriceDate
Last closeUSD 21.952026-10-01
Prenetics Global stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.27%USD 22.932026-09-24
1 month-14.96%USD 25.812026-09-01
3 month+29.65%USD 16.932026-07-02
Year to date+39.37%USD 15.752025-12-31
1 year+50.34%USD 14.602025-10-01
3 year+198.7%USD 7.352023-10-02
5 year-85.26%USD 148.952021-10-01
Since inception-80.17%USD 116.632021-07-16

Prenetics Global Financials at a Glance

Market Cap

$376.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$142.56M

Net Income (TTM)

-$67.61M

EPS (TTM)

-$4.17

P/E Ratio

-5.27

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$21.95

Volume

9

Open

$23.28

Previous Close

$21.95

Daily Range

$21.89 - $23.60

52-Week Range

$11.37 - $27.24

Estimated Earnings Date

Nov 9, 2026

PRE News

DNA with icons and doctor

Why Prenetics Global Stock Is Skyrocketing Today

Keith SpeightsJan 10, 2023

PRE: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Prenetics Global

Prenetics Global Limited is a consumer health sciences company focused on a health and longevity platform. The company operates two main brands: IM8, which offers science-backed nutritional supplements, and CircleDNA, a consumer genetic testing service providing personalized health reports.

Products and Services
  • IM8 nutritional supplements designed for health and longevity
  • CircleDNA genetic testing for personalized health insights
  • Consumer health platform integrating various health solutions
Growth Outlook
  • Revenue increased to $46.5 million in Q2 2026, up from $35.9 million in Q1 2026
  • Gross profit margin improved to 65% in Q2 2026, indicating operational efficiency
  • Strong cash position with $59 million in cash and short-term investments as of Q2 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $164 million, reflecting growth potential
  • Current ratio of 4.04, indicating strong liquidity and financial health
  • Net income of -$9 million in Q2 2026, showing ongoing investment in growth
Prenetics Global Limited is positioned in the growing consumer health sector, leveraging innovative products to meet increasing health awareness among consumers. The company's focus on genetic testing and nutritional supplements aligns with current trends in personalized health solutions. Recent financial performance indicates a positive trajectory, with significant revenue growth and improved gross profit margins. The strong liquidity position further supports the company's ability to invest in future growth initiatives. Overall, Prenetics presents an intriguing opportunity within the health and wellness market.
AI Generated • Sep 28, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

98

CEO

Sheng Wu Yeung

Website

www.prenetics.com

Headquarters

Hong Kong, HK

PRE Financials

Key Financial Metrics (TTM)

Gross Margin

62.61%

Operating Margin

-35.20%

Net Income Margin

-47.43%

Return on Equity

-49.17%

Return on Capital

-21.57%

Return on Assets

-44.00%

Earnings Yield

-18.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$376.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.14M

Volume

9

Avg. Volume

227.01K

Financials (TTM)

Gross Profit

$89.25M

Operating Income

-$50.18M

EBITDA

-$62.52M

Operating Cash Flow

-$49.39M

Capital Expenditure

$15.25M

Free Cash Flow

-$34.14M

Cash & ST Invst.

$109.39M

Total Debt

$682.00K

Prenetics Global Performance Analysis

Prenetics Global annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 13,163,841-95.2%
20232023-12-31USD 21,742,67565.2%
20242024-12-31USD 15,936,000-26.7%
20252025-12-31USD 92,390,000479.8%
Prenetics Global sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3033.2%
Q42025-12-3155.2%
Q12026-03-31-1.7%
Q22026-06-3029.3%
Prenetics Global annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -37.57154.4%
20232023-12-31USD -5.58-85.2%
20242024-12-31USD -3.71-33.6%
20252025-12-31USD -2.68-27.6%
Prenetics Global sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3043.6%
Q42025-12-31-230.2%
Q12026-03-3122.3%
Q22026-06-3061.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$46.49M

+162.9%

Gross Profit

$30.20M

+314.4%

Gross Margin

64.97%

N/A

Market Cap

$376.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.84M

N/A

Employees

98

N/A

Net Income

-$8.98M

+27.6%

EBITDA

-$21.73M

-99.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$109.39M

+294.8%

Total Debt

$682.00K

-73.5%

Accounts Receivable

$5.13M

-48.8%

Inventory

$13.99M

+225.6%

Long Term Debt

$144.00K

-86.3%

Short Term Debt

$538.00K

-64.7%

Return on Assets

-44.00%

N/A

Return on Invested Capital

-42.85%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

-$15.45M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OSUROraSure Technologies, Inc.
$3.88-1.02%
TLSITriSalus Life Sciences, Inc.
$4.15-3.71%
PROFProfound Medical Corp.
$5.85+0.86%
STIMNeuronetics, Inc.
$2.22-5.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$31.76-3.99%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$153.69+3.94%
NKENike
$35.15-0.71%
TQQQProShares Trust - ProShares UltraPro Qqq
$78.73+0.90%

Questions About PRE

What is the current price of Prenetics Global?

Prenetics Global is trading at $21.95 per share.

What is the 52-week range for Prenetics Global?

Over the past 52 weeks, Prenetics Global has traded between $11.37 and $27.24.

How much debt does Prenetics Global have?

As of the most recent reporting period, Prenetics Global reported total debt of $682.00K.

How much cash does Prenetics Global have on hand?

Prenetics Global reported $59.05M in cash and cash equivalents in its most recent financial results.

What is Prenetics Global’s dividend yield?

Prenetics Global does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services